(Q36620440)

15 August 2017

1 reference

title

Pharmacogenetics and ethical considerations: why care? (English)

1 reference

15 August 2017

0 references

Marx-Stölting L

1

1 reference

15 August 2017

10 October 2006

1 reference

The Pharmacogenomics Journal

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

5

1 reference

15 August 2017

293-296

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500425

15 August 2017

0 references

cites work

Pharmacogenomics: questions and concerns

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Ethical implications of pharmacogenetics--do slippery slope arguments matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

"Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Pharmacogenomics and children: meeting the ethical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Does Pharmacogenomics Provide an Ethical Challenge to the Utilisation of Cost-Effectiveness Analysis by Public Health Systems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

Pharmacogenetic testing, informed consent and the problem of secondary information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

7 January 2021

Racializing drug design: implications of pharmacogenomics for health disparities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

7 January 2021

The need for education in pharmacogenomics: a regulatory perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

7 January 2021

Regulatory options for pharmacogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

7 January 2021

Pharmacogenetics and the future of medical practice: conceptual considerations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500425

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500425

1 reference

15 August 2017

1 reference

PubMed ID

17033614